Cardiovascular comorbidities in spondyloarthritis

Bodur, Hatice

doi:10.1007/s10067-022-06473-9

Cited by 5 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between drugs and MACEs in SpA patients is another speculative issue [ 6 , 42 ]. Despite the cardiac toxicities, the antiinflammatory action mechanisms of these medications might attenuate the underlying atherogenic potential and serve the cardioprotection via reducing the disease activity and controlling systemic inflammation for SpA patients with different phenotypes [ 5 , 43 , 44 ]. Nevertheless, the association between the risk of CV mortality and nonsteroidal antiinflammatory drug usage in SpA patients remains controversial [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, the association between the risk of CV mortality and nonsteroidal antiinflammatory drug usage in SpA patients remains controversial [ 45 ]. The highly selective COX-2 inhibitors and steroids were the other speculative drugs leading to a higher CVD risk [ 44 ]. Kao et al [ 6 ] reported the negative impact of selective COX-2 inhibitors and corticosteroids on developing MACEs in AS patients.…”

Section: Discussionmentioning

confidence: 99%

“…There were questionable relationships between the targeted synthetic DMARDs and MACE risk in SpA patients [ 45 , 48 – 50 ]. Based on the systematic reviews and meta-analyses, the evidence that specific types of medications were associated with a higher risk of CVD is still being determined due to methodological problems [ 41 , 44 ]. We did not analyze the impact of the patient's past and current medication history on the development of CVD, considering the difficulty in collecting data about the quantity of the drugs [ 2 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Cross-sectional analysis of cardiovascular disease and risk factors in patients with spondyloarthritis: a real-life evidence from biostar nationwide registry

Duruöz,

Bodur,

Ataman

et al. 2024

Rheumatol Int

Self Cite

View full text Add to dashboard Cite

The association between spondyloarthritis and cardiovascular (CV) diseases is complex with variable outcomes. This study aimed to assess the prevalence rates of CV diseases and to analyze the impact of CV risk factors on CV disease in patients with spondyloarthritis. A multi-center cross-sectional study using the BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry) database was performed on patients with spondyloarthritis. Socio-demographic, laboratory, and clinical data were collected. Patients with and without major adverse cardiovascular events (MACE) were grouped as Group 1 and Group 2. The primary outcome was the overall group’s prevalence rates of CV disease and CV risk factors. The secondary outcome was the difference in socio-demographic and clinical characteristics between the groups and predictive risk factors for CV disease. There were 1457 patients with a mean age of 45.7 ± 10.9 years. The prevalence rate for CV disease was 3% (n = 44). The distribution of these diseases was coronary artery disease (n = 42), congestive heart failure (n = 4), peripheral vascular disorders (n = 6), and cerebrovascular events (n = 4). Patients in Group 1 were significantly male (p = 0.014) and older than those in Group 2 (p < 0.001). There were significantly more patients with hypertension, diabetes mellitus, chronic renal failure, dyslipidemia, and malignancy in Group 1 than in Group 2 (p < 0.05). Smoking (36.7%), obesity (24.4%), and hypertension (13.8%) were the most prevalent traditional CV risk factors. Hypertension (HR = 3.147, 95% CI 1.461–6.778, p = 0.003), dyslipidemia (HR = 3.476, 95% CI 1.631–7.406, p = 0.001), and cancer history (HR = 5.852, 95% CI 1.189–28.810, p = 0.030) were the independent predictors for CV disease. A multi-center cross-sectional study using the BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry) database was performed on patients with spondyloarthritis. Socio-demographic, laboratory, and clinical data were collected. Patients with and without major adverse cardiovascular events (MACE) were grouped as Group 1 and Group 2. The primary outcome was the overall group’s prevalence rates of CV disease and CV risk factors. The secondary outcome was the difference in socio-demographic and clinical characteristics between the groups and predictive risk factors for CV disease. There were 1457 patients with a mean age of 45.7 ± 10.9 years. The prevalence rate for CV disease was 3% (n = 44). The distribution of these diseases was coronary artery disease (n = 42), congestive heart failure (n = 4), peripheral vascular disorders (n = 6), and cerebrovascular events (n = 4). Patients in Group 1 were significantly male (p = 0.014) and older than those in Group 2 (p < 0.001). There were significantly more patients with hypertension, diabetes mellitus, chronic renal failure, dyslipidemia, and malignancy in Group 1 than in Group 2 (p < 0.05). Smoking (36.7%), obesity (24.4%), and hypertension (13.8%) were the most prevalent traditional CV risk factors. Hypertension (HR = 3.147, 95% CI 1.461–6.778, p = 0.003), dyslipidemia (HR = 3.476, 95% CI 1.631–7.406, p = 0.001), and cancer history (HR = 5.852, 95% CI 1.189–28.810, p = 0.030) were the independent predictors for CV disease. The prevalence rate of CV disease was 3.0% in patients with spondyloarthritis. Hypertension, dyslipidemia, and cancer history were the independent CV risk factors for CV disease in patients with spondyloarthritis.

show abstract